PROCEPT BioRobotics Corp is committed to its core values of innovation, collaboration, and patient-centricity. With a corporate philosophy focused on developing transformative solutions for patients and healthcare providers, the company aims to revolutionize the field of surgical robotics. PROCEPT BioRobotics Corp strives to enhance patient outcomes by offering its advanced Aquablation® technology, enabling precise and personalized therapy for patients with urologic conditions. By incorporating cutting-edge robotics, the company prioritizes effective treatments and improved patient experiences. Through continuous research, development, and partnerships, PROCEPT BioRobotics Corp dedicates itself to pushing boundaries and revolutionizing the healthcare industry.

PROCEPT BioRobotics Corp is primarily present in the United States.

PROCEPT BioRobotics Corp has achieved several significant milestones. The company developed and gained regulatory approval for its groundbreaking Aquablation therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH). They successfully launched their flagship product, the AquaBeam® Robotic System, in the US and other international markets. PROCEPT BioRobotics Corp expanded its global presence by establishing strategic partnerships and growing its distribution network. They have consistently demonstrated strong clinical outcomes, with numerous peer-reviewed publications supporting the effectiveness and safety of Aquablation therapy. The company's milestones highlight its commitment to revolutionizing BPH treatment and improving patient outcomes worldwide.

PROCEPT BioRobotics Corp is a renowned medical device company specializing in surgical robotics. Founded in 2002, the company has made significant strides in improving the treatment of Benign Prostatic Hyperplasia (BPH). PROCEPT BioRobotics Corp developed the revolutionary Aquablation® therapy, which utilizes advanced robotic technology to precisely and efficiently remove prostate tissue without causing significant side effects. This minimally invasive procedure has garnered recognition for its effectiveness in improving the quality of life for patients suffering from BPH. With a strong focus on innovation and patient care, PROCEPT BioRobotics Corp continues to lead the way in robotic surgical solutions for urologic conditions.

The main competitors of PROCEPT BioRobotics Corp in the market include companies such as Intuitive Surgical, Inc., Medtronic Plc, and Johnson & Johnson.

PROCEPT BioRobotics Corp is primarily active in the medical device and healthcare industries.

The business model of PROCEPT BioRobotics Corp. is focused on developing and commercializing innovative surgical technologies. The company specializes in the design and manufacturing of the AquaBeam® System, a robotic surgical platform used for treating patients with prostate conditions. This state-of-the-art technology combines the precision of a robotic arm with the benefits of water-jet technology to provide minimally invasive procedures with increased accuracy and efficiency. PROCEPT BioRobotics Corp. aims to improve patient outcomes by delivering advanced solutions in the field of urology through their AquaBeam® System, positioning themselves as leaders in robotic-assisted surgeries for prostate treatment.

Procept Biorobotics의 P/E 비율은 -38.24입니다.

Procept Biorobotics의 P/S 비율은 9.27입니다.

Procept Biorobotics에 대한 AlleAktien 품질 점수는 4/10입니다.

예상되는 Procept Biorobotics 매출은 330.87 백만 USD입니다.

예상되는 Procept Biorobotics 이익은 -80.24 백만 USD입니다.

PROCEPT BioRobotics Corp is a global provider of innovative robotic solutions for urological surgeries. The company aims to improve patient's quality of life while increasing the efficiency of surgeons. PROCEPT BioRobotics Corp's main product is the Aquablation® System, which uses robotic technology to treat benign prostatic hyperplasia. The Aquablation® System offers numerous advantages such as faster recovery, reduced risk of complications, and immediate symptom relief. The company also offers training and education services to healthcare professionals. PROCEPT BioRobotics Corp follows a "Razor-and-Blades" business model, offering the Aquablation® System at an affordable price while generating revenue from the regular supply of consumables. The company prioritizes regulatory compliance and has implemented a global quality management system. In summary, PROCEPT BioRobotics Corp is a leading company in the field of robotic urology, providing an excellent alternative to traditional surgical treatments.

Procept Biorobotics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Procept Biorobotics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Procept Biorobotics의 ISIN은 US74276L1052입니다.

Procept Biorobotics의 티커는 PRCT입니다.

지난 12개월 동안 Procept Biorobotics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Procept Biorobotics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Procept Biorobotics의 현재 배당 수익률은 입니다.

Procept Biorobotics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Procept Biorobotics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Procept Biorobotics은 '건강' 섹터에 속합니다.

Procept Biorobotics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Procept Biorobotics는 0 USD를 배당금으로 지급했습니다.

Procept Biorobotics의 배당금은 USD에 지급됩니다.